This document is a publication of a new US patent application (US20260083768A1) from the USPTO. It describes methods for treating rhegmatogenous retinal detachment (RRD) and improving visual outcomes through inflammasome inhibition. The application was filed on September 8, 2023, and published on March 26, 2026, listing Jayakrishna Ambati, Peirong Huang, and Kameshwari Ambati as inventors.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in therapeutic approaches for retinal conditions, which may be of interest to pharmaceutical and medical device companies involved in ophthalmology research and development. Compliance officers in these sectors should be aware of emerging intellectual property in this therapeutic area.